You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The nucleic acid diagnostic platform they are developing doesn't require expensive optics, and it could be available as a manufacturing prototype in about a year.
Their approach is based on measuring the mechanical fluctuations of bacteria, and the effect that antibiotics have on those fluctuations.
Astrego Diagnostics has been founded to commercialize the technology for the rapid detection of bacterial antibiotic resistance in UTIs.
The firm said that a number of hospitals and labs are expected to evaluate the panel, presenting it with about a $2.0 million annual revenue opportunity.